Comparison of quality of life in patients with endometriosis undergoing treatment with progestins, oral contraceptives pills (OCP), and GnRH agonists

Mania Kaveh, Shahla Chaichian, Abolfazl Mehdizadeh Kashi, Maryam Mohsenikia, Malihe Afrouzeh, Kambiz Sadegi
BMC women's health · 2025 · vol. 25(1) , pp. 397 · doi:10.1186/s12905-025-03937-3 · PMID:40836300 · W4413357347
article OA: gold CC0 ⤵ 1 in-corpus citation
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study compared quality of life in endometriosis patients treated with progestins, OCPs, and GnRH agonists, finding no significant differences among the three groups.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This prospective, observational comparative study enrolled women aged 18–45 with imaging-confirmed endometriosis at a single hospital in Zabol, Iran (2022–2024) and assessed quality of life after at least three months of treatment with progestins, oral contraceptive pills (OCPs), or GnRH agonists. Quality of life was measured using the Endometriosis Health Profile-30 (EHP-30) questionnaire (Persian version), and groups were compared on domain scores and related demographic/lifestyle variables. While significant differences were reported across some demographic and symptom-related variables (nutritional status, dyschezia, and psychological disorders), there were no statistically significant differences in overall quality-of-life scores between the three treatment groups (P = 0.197), with the main limitation being a single-site design and relatively small GnRH-agonist group size. This paper is centrally about endometriosis — it compares EHP-30 quality-of-life outcomes across progestins, OCPs, and GnRH agonist treatments in women with endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: The objective of this study was to compare the quality of life in patients with endometriosis undergoing treatment with progestins, OCPs, and GnRH agonists. METHODS: This prospective, observational, and comparative study was conducted on patients with endometriosis at Amir al-Momenin Hospital (Zabol, Iran) from 2022 to 2024. The Endometriosis Health Profile (EHP-30) questionnaire was used to utilized patients' quality of life. RESULTS: The study included three groups of women using OCPs, progestins, and GnRH agonists, consisting of 39, 74, and 22 participants, respectively. No significant differences were observed among the three groups with regard to occupation, education, marital status, physical activity, coffee consumption, or tobacco and alcohol use. However, a number of significant differences were identified in nutritional status, dyschezia, and psychological disorders. No statistically significant differences were observed in quality-of-life scores among the three groups (P = 0.197). CONCLUSION: The three treatment approaches demonstrated comparable outcomes in terms of the quality of life of patients diagnosed with endometriosis. However, the observed differences in certain demographic and psychological health variables underscore the necessity to consider factors beyond pharmacological treatment to enhance the quality of life in these patients.

My notes (saved in your browser only)

Outcome instruments

EHP-30 VAS-pain

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-06-04T00:31:09.867728+00:00
License: CC0 · commercial use OK